Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Bone Remodeling01:40

Bone Remodeling

40.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment duration for romosozumab - Authors' reply.

The lancet. Diabetes & endocrinology·2026
Same author

Intermittent parathyroid hormone employs autonomous and non-autonomous mechanisms to drive osteogenesis from Ebf3-expressing skeletal progenitor cells.

bioRxiv : the preprint server for biology·2026
Same author

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.

The lancet. Diabetes & endocrinology·2026
Same author

Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

The comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength.

JBMR plus·2025
Same author

Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025

Related Experiment Video

Updated: Dec 31, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

18.1K

Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study.

Houchen Lyu1,2,3,4, Sizheng S Zhao1,5, Kazuki Yoshida1

  • 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

The Journal of Clinical Endocrinology and Metabolism
|January 3, 2020
PubMed
Summary

Delays in denosumab injections negatively impact bone mineral density (BMD) response. Maintaining timely administration is crucial for optimal therapeutic effects in osteoporosis management.

Keywords:
Osteoporosisbone mineral densitydenosumabdosing delay

More Related Videos

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.5K
Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
09:02

Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population

Published on: January 31, 2025

1.4K

Related Experiment Videos

Last Updated: Dec 31, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

18.1K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.5K
Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
09:02

Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population

Published on: January 31, 2025

1.4K

Area of Science:

  • Osteoporosis Research
  • Pharmacology
  • Bone Metabolism

Background:

  • Denosumab discontinuation causes rapid loss of therapeutic benefits.
  • Limited data exist on the impact of delayed denosumab injections on bone mineral density (BMD).

Purpose of the Study:

  • To investigate the association between delayed denosumab injections and changes in BMD.
  • To assess the impact of denosumab administration intervals on treatment efficacy.

Main Methods:

  • Retrospective analysis of electronic medical records from two academic hospitals (2010-2017).
  • Inclusion criteria: patients >45 years receiving at least two 60 mg denosumab doses.
  • Adherence categorized by medication coverage ratio (MCR): good (≤7 months), moderate (7-10 months), poor (≥10 months).

Main Results:

  • Analysis included 151 patients and 938 denosumab injections; mean age 69 years, 95% female.
  • Good adherence (≤7 months) showed higher annualized BMD increase: lumbar spine 3.9%, total hip 2.1%.
  • Poor adherence (≥10 months) resulted in significantly lower BMD increases: lumbar spine 1.4%, total hip 0.6% (P for trend <0.01).

Conclusions:

  • Longer intervals between denosumab injections are linked to reduced BMD response at the spine and hip.
  • Strategies are needed to ensure timely denosumab administration in clinical practice.
  • Optimizing injection schedules is vital for sustained therapeutic outcomes in osteoporosis patients.